Bachem Holding AG Stock price Swiss Exchange
Equities
BANB
CH0012530207
Biotechnology & Medical Research
Sales 2024 * | 618M 685M | Sales 2025 * | 823M 912M | Capitalization | 6.48B 7.18B |
---|---|---|---|---|---|
Net income 2024 * | 127M 141M | Net income 2025 * | 160M 177M | EV / Sales 2024 * | 10.4 x |
Net cash position 2024 * | 78.09M 86.56M | Net Debt 2025 * | 28.4M 31.48M | EV / Sales 2025 * | 7.91 x |
P/E ratio 2024 * |
51.6
x | P/E ratio 2025 * |
40.2
x | Employees | 2,006 |
Yield 2024 * |
1% | Yield 2025 * |
1.04% | Free-Float | 94.31% |
Latest transcript on Bachem Holding AG
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 18-12-31 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 12-04-24 |
Director/Board Member | 51 | 11-04-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 18 M€ | +7.04% | - |
1st Jan change | Capi. | |
---|---|---|
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |